Approximately 20–25% of all BC cases have an overexpression of the human epidermal growth factor receptor 2 (HER2), which is associated with more frequent recurrences after initial treatment, as well as higher risk of distant metastases [75]. Here, ERBB2 is linked to breast cancer.